



8th Annual Emirates
Cardiac Society
Conference



ACC Middle East
Conference 2017



DUBAI

OCTOBER 19 – 21, 2017



UNIQUE EDUCATIONAL EXPERIENCE
IN YOUR REGION

The Role of Tobacco in Cardiovascular Disease and Disability; Effects of secondary- and tertiary-tobacco use

Georges A. Saade, MD, FESC, FACC

Associate Prof. Lebanese University

Chair of the Cardiovascular Prevention WG

Lebanese Society of Cardiology


Consultant Cardiologist, Bellevue Medical Center



ACC Middle East
Conference 2017

The Tobacco Epidemic - Today

TOBACCO USE IS A RISK FACTOR FOR SIX OF THE EIGHT LEADING CAUSES OF DEATH IN THE WORLD




ACC Middle East
Conference 2017

The Tobacco Epidemic - Tomorrow

TOBACCO WILL KILL OVER 175 MILLION PEOPLE WORLDWIDE BETWEEN NOW AND THE YEAR 2030

Cumulative tobacco-related deaths, 2005–2030



ACC Middle East
Conference 2017

The Tobacco Epidemic is about to Get Much Worse

Tobacco currently kills more than **5 million/yr** but this will increase to over **8 million/yr in 2030**

If current smoking patterns continue, the death toll from tobacco use will be:

2000 – 2025 ~ **150M**

2025 – 2050 ~ **300M**

2050 – 2100 > **500M**

(Peto, WHA 2008)


TOTAL for 20th Century 0.1 billion

TOTAL for 21st Century 1 billion


(half the deaths in middle age)



Tobacco – It's no longer only a problem in developed countries



Where is the burden increasing the fastest, 1990 to 2020?



25  25

Reducing premature mortality from
Cardiovascular Disease (CVD)
by **25%** by the year **2025**




ACC Middle East
Conference 2017

Projected Global Tobacco-Caused Deaths

By cause, 2015 baseline scenario

Totals might not sum due to rounding.



WORLD LUNG
FOUNDATION



ACC Middle East
Conference 2017

"I'm going to grow a hundred years old!"

...and possibly she may—for the amazing strides of medical science have added years to life expectancy

It's a happy, warm and wonderful scene that this five-year-old child, in your own child, has a life expectancy almost a whole decade longer than was her mother's, and a good 10 to 20 years longer than that of her grandmother. Not only the expectation of a longer life, but of a life by far healthier. Thank medical science for that. Thank your doctor and thousands like him... taking steadily, often with little or no public recognition... that you and yours may enjoy a longer, better life.



According to a recent Nationwide survey:

More Doctors smoke Camels than any other cigarette!

NOT ONE, but three outstanding independent research organizations confirmed this survey. And they asked not just a few thousand, but 111,707, doctors from coast to coast to name the cigarette they themselves preferred to smoke.

The greatest cause is by the thousands... from general physicians, diagnosticians, surgeons, etc., and men and women specialists too. The most trusted brand name Camel.

If you are not now smoking Camels, try them. Compare them carefully. See how the full rich flavor of Camel's smooth tobacco notes your taste. See how the cool mellowness of a Camel suits your throat. Let your "E-Zone" tell you your rights.



CAMELS Cestlier Tobaccos

BRITISH MALE DOCTORS' STUDY

Prospective study of 34,439 male doctors studied from 1951 to 2001

On average, cigarette smokers die about 10 years younger than do nonsmokers.

At least half of chronic smokers will die due to a tobacco-related disease.

Doll et al. (2004). *BMJ* 328(7455):1519–1527.




ACC Middle East
Conference 2017



BRITISH MALE DOCTORS' STUDY: LIFE LOST

On average, life-long smokers lose 10 years of healthy life



Survival from age 35 for continuing cigarette smokers and lifelong non-smokers among UK male doctors born 1900-1930, with percentages alive at each decade of age.







ACC Middle East
Conference 2017

Doll R et al. BMJ 2004;328:1519

BMJ



BRITISH MALE DOCTORS' STUDY: STOPPING SMOKING & YRS of LIFE GAINED



STOPPING WORKS: stopping smoking at ages 30, 40, 50, and 60 resulted in 10, 9, 6, and 3 years of life gained, respectively.



ACC Middle East
Conference 2017

Doll R et al. BMJ 2004;328:1519

BMJ

HEALTH CONSEQUENCES of SMOKING

- Cardiovascular Diseases
- Coronary artery disease
- Heart failure
- Abdominal aortic aneurysm
- Cerebrovascular disease
- Peripheral arterial disease
- Sudden death
- Occlusion of bypass grafts & stents
- Poor surgical outcomes

- Other

- Numerous cancers
- Pulmonary diseases
- Reproductive effects
- Eye disease
- Osteoporosis
- Type 2 diabetes
- Periodontitis


USDHHS. (2004). *The Health Consequences of Smoking: A Report of the Surgeon General*.



ACC Middle East
Conference 2017

The 2004 Surgeon General's Report

Pathophysiological Mechanisms of Tobacco-Related CVD



Smokers are not the only ones sickened and killed by tobacco:

Non-smokers who breathe air **containing second-hand tobacco smoke** also face serious and often fatal health consequences.

Research shows that globally, one third of adults are regularly exposed to second-hand tobacco smoke and about **600 000** people die each year prematurely as a result of exposure to second-hand smoke.


Of the **600 000** deaths, **430 000** are among adults, of whom **64%** are women. **Twenty-eight per cent** of the second-hand smoke deaths are among children.



ACC Middle East
Conference 2017

DEATHS GLOBALLY from SECONDHAND SMOKE

Secondhand Smoke is tobacco smoke that is exhaled by smokers or given off by burning tobacco



ACC Middle East
Conference 2017

SECONDHAND SMOKE & CVD

- Second-hand smoke (SHS) causes premature death and disease in nonsmokers:
 - Immediate adverse effects on the CV system – **same effects as active smoking**
 - Increased risk for heart disease & lung cancer
 - Bans on smoking in public places reduce exposure to SHS and reduce heart attacks

There is no safe level of second-hand smoke

USDHHS. (2006). *The Health Consequences of Involuntary Exposure to Tobacco Smoke: Report of the Surgeon General.*

Institute of Medicine. *Secondhand Smoke Exposure and Cardiovascular Effects : Making Sense of the Evidence. Exposure.* Washington, D.C.: The National Academies Press; 2010.



ACC Middle East
Conference 2017

Secondhand Smoke

Exposure to Secondhand Smoke





FIGURE 9.1 Mainstream smoke is inhaled by the smoker during puffing, and to a small extent diffuses through the cigarette paper. Between puffs, the smoker emits exhaled mainstream smoke, and the burning end of the cigarette emits sidestream smoke. The combination of sidestream (~90%) and exhaled mainstream smoke (~10%) is called secondhand smoke. An older term for secondhand smoke is environmental tobacco smoke.



META-ANALYSIS of CHD RISK DUE to CHRONIC SHS among NEVER-SMOKERS

- Overall $RR = 1.78$ for active smokers
- Overall $RR = 1.31$ for passive smoking
- Most of the SHS exposures were spousal




Long-term SHS exposure in the work or home is associated with a 30% increased risk for CHD in adult nonsmokers




HEAVY SHS EXPOSURE is LIKE BEING a LIGHT SMOKER

"Light passive" refers to the lowest quarter of cotinine concentration among nonsmokers (0-0.7 ng/ml), "heavy passive" to the upper three-quarters of cotinine concentration combined (0.8-14.0 ng/ml), "light active" to men smoking 1-9 cigarettes a day.




Smoking Bans Prevent Heart Attacks!!

- IOM Report: “Secondhand Smoke Exposure and Cardiovascular
- Effects: Making Sense of the Evidence”
 - 11 studies reviewed
 - All show an association between smoking bans and a reduced incidence of heart attacks
 - Reductions: -6% to -47%
- “[B]ased on its review of the available literature, the committee concludes that there is a causal association between smoking bans and decreases in heart attacks”
- No data from low- and middle-income countries



ACC Middle East
Conference 2017


REDUCING SHS EXPOSURE REDUCES HOSPITAL ADMISSIONS for MI



Studies reporting reduction in hospital admissions for acute MI/acute coronary syndrome following smoke-free legislation

One study has been published that did not detect evidence of a reduction in hospital admissions for acute heart disease (Edwards et al., 2008)

Potential Mechanisms



- Two studies evaluated impacts among non-smokers
 - Both found a decrease in coronary events (Scotland, Indiana)
- Brief exposure to tobacco smoke can lead to endothelial dysfunction, increased thrombosis, inflammation, and impacts on plaque stability.
 - All are on the pathway to acute MI.



AFTER the LAST CIGARETTE...

< 30 min	Blood pressure and pulse return to normal
8 hr	CO levels in blood return to normal
24 hr	Endothelial better, chance of heart attack decreases
48 hr	Nerve endings begin regrowth
72 hr	Breathing becomes easier; lung capacity increases
2-12 wks	Lung function increases 30%; circulation improves
1 year	Risk of CHD is half that of a smoker
3 years	MI risk is similar to that of never-smokers
5-15 years	Stroke risk reduced to that of never-smokers



SMOKING CESSATION is a TREATMENT for CVD

- Standard treatments reduce the risk of death in patients with CVD by 15–35%
 - Aspirin = 15%
 - Beta blockers = 23%
 - ACE inhibitors = 23%
 - Statins = 29–35%
- Smoking cessation in patients with CVD reduces the risk of death by 36% and reduces the risk of future cardiac events by 50%



TREATING TOBACCO is a GOLD STANDARD TREATMENT

Intervention	Outcome	NNT
Statins	Prevent 1 death over 5 years	107
Aspirin	Prevent 1 MI over 5 years	118
Antihypertensive therapy	Prevent 1 stroke, MI, death over 1 year	700
Cervical cancer screening	Prevent 1 death over 10 years	1140
MD 5 min advice to stop smoking	Prevent 1 premature death	80
+ cessation medication	Prevent 1 premature death	38-56
+ behavioral support	Prevent 1 premature death	16-40

NNT = Number Needed to Treat

Anthonisen, 2006, Ann Intern Med; McQuay & Moore, 2006, Bandolier; Gates 2001, Am Fam Phys; Cochrane Reviews by Stead, Bergeson, et al., 2008; Stead, Perera, et al. 2012; Stead & Lancaster, 2012; Cahill et al., 2010; and USPSTF, 2009



ACC Middle East
Conference 2017



TOBACCO TREATMENT is COST EFFECTIVE

- Tobacco cessation counseling + medications = **\$2587** per life-year saved (Cromwell et al., 1997)
 - Far less than the cost-effectiveness conventional benchmark of \$50,000 per life-year gained
- ***Tobacco cessation counseling and medication are highly cost-effective relative to other reimbursed treatments and should be provided to all smokers*** US Agency for Healthcare Research & Quality

WHY ADDRESS TOBACCO in CARDIOLOGY?

- Smoking and SHS are independent and synergistically linked with other CVD risk factors
- Quitting smoking: improves survival, improves quality of life, reduces risk of future CVD events
- Reducing SHS: reduces hospitalizations for MI

TREATING TOBACCO is a GOLD STANDARD TREATMENT for CVD



ACC Middle East
Conference 2017

RELAPSE following MI HOSPITALIZATION

- Most patients return to smoking within 6 months following an MI hospitalization
- Patients more likely to stay smoke-free if...
 - Hospital has a cessation program
 - Patient referred for cardiac rehab
 - Less depressive symptoms during hospitalization

Dawood et al. (2008). *Arch Intern Med* 168:1961-1967.



ACC Middle East
Conference 2017

CARDIOLOGISTS in PRACTICE

- Anonymous survey of 326 cardiologists in Spain
 - 11% response rate, so best case scenario
- 3 in 4 said they always ask patients about smoking and recommend that smokers quit
- 1 in 5 had cessation print materials in the office
- 2 in 5 followed up with patients to check on progress
- Majority were unfamiliar with cessation meds (73%) and wanted to improve their tobacco treatment skills (71%)



This training is designed to meet the needs of cardiologists for effectively treating tobacco in practice



FUNDAMENTAL PRINCIPLE

Treat smoking in exactly the same way that you would manage any other cardiovascular disease risk factor

A. Pipe (2013) The Ottawa Model of Smoking Cessation



ACC Middle East
Conference 2017

THE CARDIOLOGY TEAM' S RESPONSIBILITY

The cardiology team has a
professional obligation
to address tobacco use & exposure

ADDRESSING TOBACCO USE & EXPOSURE
is an ESSENTIAL COMPONENT of CVD TREATMENT
for ALL PATIENTS



ACC Middle East
Conference 2017

Cardiologists have an Important Responsibility

Refuse collaboration and funding from the Tobacco Industry

Be non-tobacco using role models

Advise tobacco users to quit and tell all patients to avoid SHS

Comply with the Code of Practice on Tobacco Control for Health Professional Organizations



Approach tobacco use as a chronic disease; document smoking status

Support the WHO FCTC

Help reduce premature mortality from CVD by 25% by 2025

Ensure cessation support is accessible

Provide medical students with the skills and motivation to treat tobacco

Support smoke-free healthcare and educational facilities

use



ACC Middle East
Conference 2017